The Microscopic Frontier: Why Controlling Graft Microstructure in Covered Stents is Critical for Clinical Success

The landscape of cardiovascular and endovascular interventions has been fundamentally transformed by the evolution of the stent. What began as bare-metal scaffolds designed simply to hold a collapsed vessel open has evolved into highly sophisticated medical devices known as covered stents, or stent grafts. By wrapping the traditional metallic backbone in a thin polymeric membrane, engineers created a device capable of doing much more than providing structural support. Covered stents can seal life-threatening aneurysms, exclude fistulas, bridge vascular traumas, and establish reliable transjugular intrahepatic portosystemic shunts (TIPS).

However, the addition of a polymeric cover introduces a profound layer of biological complexity. When a synthetic material is introduced into the human vascular system, the body does not interact with the device as a single, macroscopic object. Instead, blood cells, proteins, and surrounding tissues interact with the graft at the microscopic and nanoscopic levels. This microscopic landscape,the microstructure of the graft,dictates the entire cascade of biological responses.

Understanding, engineering, and strictly controlling this microstructure is not merely a matter of manufacturing optimization; it is a critical clinical imperative. This article delves deeply into why controlling the graft microstructure of covered stents is so vital, how microscopic architecture dictates thrombus formation and excessive tissue growth, the exact parameters that demand rigorous control, the clinical dangers of manufacturing variances, and how advanced manufacturing partners like Medibrane provide the exact technological solutions required to master this microscopic frontier.

The Anatomy of a Covered Stent and the Role of Microstructure

To comprehend the importance of microstructure, one must first look at a covered stent through the lens of a scanning electron microscope (SEM). To the naked eye, a stent graft appears to be a metal mesh wrapped in a smooth, continuous plastic film—often made of expanded polytetrafluoroethylene (ePTFE), polyurethane (PU), or Dacron (polyethylene terephthalate).

Under high magnification, however, the "smooth" surface is revealed to be a complex, three-dimensional terrain. Depending on the material and the manufacturing process, this terrain consists of interconnected pores, solid nodes, stretching fibrils, and woven or spun polymer fibers.

The term microstructure refers to the precise spatial arrangement and dimensional characteristics of these microscopic features. The human body is highly attuned to surface topographies on this scale. Endothelial cells (which line the inside of healthy blood vessels) measure roughly 10 to 30 micrometers in width and 30 to 50 micrometers in length. To these cells, the stent's microstructure is a physical landscape they must traverse, adhere to, and colonize. If the terrain is properly engineered, the body accepts the graft, incorporating it into the vascular wall through a healthy healing process. If the terrain is poorly designed or inconsistently manufactured, the body identifies the graft as a persistent foreign invader, triggering cascades that lead to catastrophic clinical failure.

The Biological Battleground: How Microstructure Drives Thrombus Formation

One of the most immediate and dangerous risks following the implantation of a covered stent is early-phase thrombosis—the formation of a blood clot inside the graft that can completely occlude the vessel.

The moment a synthetic graft is deployed, it is exposed to the complex fluid dynamics of circulating blood. The inherent bio-incompatibility of most raw synthetic materials means that blood coagulation can be induced rapidly, leading to swift thrombus formation if the surface is not meticulously controlled (Goldman et al., 2023). Within seconds of contact, plasma proteins such as fibrinogen and fibronectin adsorb onto the polymer surface. Platelets passing by detect this protein layer, become activated, and begin to aggregate, forming the initial scaffolding for a full-blown thrombus.

The microstructure of the graft plays a leading role in accelerating or mitigating this coagulation cascade through its direct impact on hemodynamics and wall shear stress. Blood flow within a healthy vessel is typically laminar, moving smoothly in parallel layers. When blood encounters the surface of a covered stent, the friction generated by the graft's microscopic topography can disrupt this laminar flow.

By strategically reducing the coefficient of friction through microstructural engineering, the flow regime can be maintained in a desirable laminar state, which minimizes energy loss, reduces the risk of thrombosis, and ensures optimal oxygen delivery to surrounding tissues (Ahadi et al., 2024). Conversely, if the microstructure is excessively rough, inconsistent, or features inappropriately sized protrusions, it creates localized turbulence and abnormal wall shear stresses. The relationship between shear stress and thrombosis is complex: while low and oscillating shear stress is associated with increased in-stent restenosis and thrombosis, high shear stress in the range of 60 dynes/cm² (6 Pa) and above can directly activate platelets and promote thrombus formation, particularly when exposure is sustained (Ahadi et al., 2024).

Therefore, controlling the microstructure is essentially the act of controlling fluid mechanics at the boundary layer. A highly uniform, optimized pore and fiber structure prevents the localized pooling of blood and excessive friction that act as the primary mechanical catalysts for clot formation.

Excessive Growth: The Mechanics of Neointimal Hyperplasia

If early-phase thrombosis is the primary acute threat to a stent graft, neointimal hyperplasia (NH) is the primary chronic threat. NH is the abnormal, excessive proliferation of tissue within the lumen of the vessel, which progressively narrows the artery and leads to late-stage restenosis (re-narrowing) and graft failure.

The pathogenesis of neointimal hyperplasia is a direct result of the biological response to both surgical injury and the physical presence of the synthetic graft material. The goal of any stent graft implantation is complete endothelialization—the formation of a single, healthy layer of endothelial cells over the blood-contacting surface of the graft. This layer acts like a non-stick coating, rendering the stent invisible to the body's clotting mechanisms.

However, achieving this requires a delicate microstructural balance. If the graft's microstructure fails to facilitate rapid endothelial cell migration, the body's inflammatory and healing responses go into overdrive. Injury-induced neointimal hyperplasia and the incomplete endothelialization of the injured arterial segments are the primary drivers of adverse clinical events such as in-stent restenosis and delayed stent thrombosis (Janjic et al., 2017).

The cellular timeline of NH is aggressive. The physical trauma of graft placement, combined with the presence of the foreign synthetic material, initiates a massive inflammatory response. Within hours of the graft being deployed, fibroblasts located in the adventitia (the outer layer of the blood vessel) transform into highly active myofibroblasts (Li et al., 2008). These transformed cells rapidly proliferate and migrate aggressively toward the inner lumen of the vessel, where they begin depositing thick layers of extracellular matrix, serving as the primary biological drivers of NH formation (Li et al., 2008).

Simultaneously, smooth muscle cells (SMCs) in the media layer of the artery are triggered by inflammatory cytokines to proliferate and migrate into the graft area. Studies examining the timeline of this excessive growth have shown that while early cellular activity is concentrated in the outer vessel layers, pathological cell proliferation within the neointima increases in a rapid, linear fashion beginning approximately two weeks post-implantation (Li et al., 2008).

The microstructure of the stent graft cover directly dictates the severity of this response. If the pores are too large, excessive amounts of inflammatory cells and myofibroblasts easily infiltrate the graft wall, causing massive tissue buildup. If the pores are too small, healthy endothelial cells cannot gain a foothold to cover the surface and signal the body to halt the inflammatory cascade. The failure to precisely control the physical architecture of the polymer results in a continuous cycle of inflammation, cellular hyper-proliferation, and eventual occlusion of the life-saving device.

Key Microstructural Parameters Demanding Strict Control

To engineer a graft that promotes rapid healing while resisting thrombosis and hyperplasia, manufacturers must exert absolute control over several distinct microstructural parameters:

1. Pore Size

Pore size is arguably the most consequential parameter of a polymeric stent cover. The diameter of the pores determines which biological components can cross the membrane and which are excluded. In advanced applications like flow-diversion for aneurysm treatment, the microstructural dimensions of the stent play a commanding role. Advanced numerical studies have shown that the change in the average pore size of the stent device is the sole microstructural parameter that demonstrates a highly strong correlation with the actual reduction in aneurysmal hemodynamics and critical pressure drops (Zhang et al., 2021).

Too small: Pores under 10 micrometers may prevent any cellular infiltration, effectively starving the inner surface of the graft of the biological building blocks needed to form a healthy endothelial layer.

Too large: Pores exceeding 50-100 micrometers (depending on the specific vascular application) may allow excessive blood leakage immediately after implantation and permit uninhibited migration of hyperplastic smooth muscle cells.

2. Porosity (Void Volume)

Porosity refers to the overall percentage of empty space within the material compared to solid mass. While pore size dictates what can pass through, porosity dictates how much can pass through, as well as the mechanical properties of the cover. High porosity ensures excellent flexibility and allows for necessary nutrient diffusion, but it compromises the structural integrity and burst strength of the graft. Controlling porosity ensures the stent remains highly deliverable (capable of being compressed into a catheter) without tearing upon deployment.

3. Fiber Diameter and Architecture

In materials that rely on stretched nodes and fibrils (like ePTFE), the physical shape of the structural elements matters. For example, ePTFE covers rely heavily on their unique internodal architecture for their mechanical behavior. When ePTFE is stretched during manufacturing or deployment, it exhibits high radial flexibility; however, this elongation fundamentally alters the structural arrangement of the fibers and changes the functional porosity of the membrane (Chen et al., 2018). If the fiber architecture is not stabilized, the simple act of deploying the stent can ruin its carefully designed microstructure.

4. Surface Topography and Roughness

As discussed, the blood-contacting surface must maintain an ultra-low coefficient of friction. Nanoscale roughness can provide beneficial anchoring points for healthy endothelial cells, but microscale roughness will trap platelets and induce turbulence. The transition from the bare metal strut to the polymeric web must be seamless.

The Domino Effect of Manufacturing Variances on Clinical Results

Understanding the ideal microstructure is only half the battle; consistently manufacturing it is an entirely different engineering challenge. Polymers are notoriously temperamental materials. Their microscopic structures are highly sensitive to variations in temperature, ambient humidity, mechanical tension, and chemical formulation during the manufacturing process.

Consider the processes used to create expanded membranes. If the ambient temperature in the cleanroom fluctuates slightly, or if the pull-speed of a stretching machine varies by a fraction of a millimeter per second, the resulting polymer will have an inconsistent node-to-fibril ratio.

The clinical consequences of manufacturing variances are severe. A stent graft with high structural variance might feature optimal 30-micrometer pores on its proximal end, but practically impermeable 2-micrometer pores on its distal end. Once implanted, the proximal end will heal and endothelialize normally, while the distal end will remain bare, exposing raw synthetic material to the blood stream for months. This localized area will inevitably trigger chronic inflammation, turbulent blood flow, and localized neointimal hyperplasia, ultimately threatening the patient's life.

Regulatory agencies demand tight quality control because batch-to-batch or stent-to-stent variability transforms a carefully engineered medical device into an unpredictable clinical gamble. Controlling microstructure means absolutely eliminating manufacturing variances.

The Medibrane Advantage: Paradigm-Shifting Microstructure Control

Overcoming the profound challenges of microstructural variance requires specialized technology, deep materials science expertise, and a fundamental rethinking of how stent grafts are assembled. Medibrane, an industry-leading contract manufacturer of medical device coatings and polymeric covers, provides comprehensive, proprietary solutions designed explicitly to master the microscopic architecture of stent grafts.

Instead of relying on conventional methods that often compromise the polymer's architecture during the bonding phase, Medibrane utilizes an innovative, sequential manufacturing approach. By separating membrane creation from scaffold bonding, and by employing proprietary adhesion technologies, Medibrane ensures that the engineered microstructure remains totally undisturbed from the cleanroom to the operating room.

1. Customized Raw Materials for Baseline Predictability

Microstructural control begins long before the polymer is shaped; it begins at the chemical level. Commercially available off-the-shelf polymers often possess batch-to-batch molecular weight variations and additive inconsistencies that translate directly into physical microstructural variances during manufacturing. To eliminate this foundational instability, Medibrane utilizes customized raw materials. By carefully tailoring the polymer resin formulation—controlling aspects such as viscosity, molecular chain entanglement, and specific rheological properties—Medibrane establishes a highly predictable baseline. This customized approach ensures that when the material is processed, it behaves uniformly, allowing for the precise and repeatable generation of the desired pore size, internodal distances, and overall porosity without the unpredictable deviations common in standard industry materials.

2. Decoupled Membrane Generation and Pre-Evaluation

One of the greatest flaws in traditional stent graft manufacturing is the application of the polymer directly onto the metallic stent scaffold as a primary step. If the coating process yields an incorrect pore size or an inconsistent microstructure, the entire expensive device must be scrapped. Furthermore, evaluating the exact microstructural properties of a polymer once it is already interwoven with metal struts is highly complex and prone to measurement errors.

Medibrane has revolutionized this workflow. Rather than coating the scaffold directly, Medibrane creates the membrane independently on a specialized mandrel. This decoupled approach is a game-changer for quality control. Once the membrane is formed on the mandrel, it can be subjected to exhaustive, unhindered analysis. Engineers can evaluate the membrane using high-resolution scanning electron microscopy (SEM) and advanced porosimetry to confirm that the pore size, porosity, and surface topography match the exact clinical specifications down to the micrometer. Only after the membrane has passed these rigorous microstructural evaluations is it approved to be bonded to the metal scaffold. This guarantees that absolutely no microstructural variances make their way into the final assembled medical device.

3. Adhera Surface Activation Technology

Bonding a delicate, pre-evaluated polymeric membrane to a bare metal stent presents a significant challenge. Traditional methods often rely on aggressive chemical adhesives that can seep into the membrane and occlude the carefully measured pores, or they require bulky physical sutures that create micro-turbulences in the bloodstream and act as nidi for thrombus formation.

Medibrane overcomes this through its proprietary Adhera™ surface activation technology. Before the pre-evaluated membrane is applied, the bare metal stent scaffold (whether Nitinol, Cobalt Chromium, or Stainless Steel) undergoes the Adhera process. This technology fundamentally alters the surface energy and chemical topography of the metal struts at a molecular level, transforming an inert metal surface into a highly receptive bonding platform. Crucially, Adhera achieves this without altering the bulk mechanical properties of the stent and without adding any measurable thickness to the struts. This ensures a flawless, uniform interface between the metal and the polymer.

4. Sutureless Lamination Technology: Preserving the Pore

Once the membrane is validated and the scaffold is activated via Adhera, the two components must be joined. Historically, the industry standard for bonding materials like ePTFE has been sintering—a process that involves exposing the polymer and stent to extreme heat and pressure to force a mechanical bond. While effective for adhesion, sintering is devastating to microstructure. The intense thermal energy melts, warps, and distorts the node-and-fibril architecture of the polymer. A membrane that was evaluated to have a perfect 30-micrometer pore size prior to sintering will often emerge from the heat cycle with collapsed pores, fused fibrils, and wildly inconsistent porosity.

Medibrane completely bypasses this destructive thermal cycle by utilizing its proprietary Sutureless Lamination Technology. This advanced bonding process leverages the highly reactive surface created by the Adhera technology to seamlessly laminate the pre-evaluated membrane directly onto the scaffold.

Because Sutureless Lamination does not rely on the aggressive melting temperatures and crushing pressures of traditional sintering, the polymer's architecture is left entirely intact. The exact pore size and uniform microstructure that were measured and validated on the mandrel are perfectly preserved on the final device. Furthermore, as the name implies, this technology eliminates the need for bulky physical sutures to anchor the graft, resulting in an ultra-low profile device with a perfectly smooth, disruption-free transition between the stent and the covering. This incredibly smooth topography minimizes wall shear stress, significantly reducing the risk of early-phase thrombosis and ensuring the rapid, healthy endothelialization required to prevent neointimal hyperplasia.

Conclusion

The line between a successful endovascular intervention and a dangerous clinical complication is drawn on a microscopic scale. The graft microstructure of a covered stent is not a passive barrier; it is an active biological interface that dictates hemodynamics, triggers or suppresses blood coagulation, and controls the complex cellular migration pathways that lead to either rapid healing or chronic neointimal hyperplasia.

As cardiovascular therapies continue to push the boundaries of minimally invasive care, the tolerance for manufacturing variance drops to zero. Medical device companies must view the polymeric cover not as an accessory to the metal stent, but as the critical tissue-interface of the device. By partnering with specialized manufacturers like Medibrane, innovators can leverage groundbreaking approaches—from customized raw materials and pre-evaluation to Adhera surface activation and Sutureless Lamination—to exert absolute, uncompromising control over their device's microscopic landscape. In the exacting world of covered stents, mastering the microstructure without destroying it during assembly is the ultimate key to unlocking safe, predictable, and life-saving clinical results.

References

Ahadi, F., Azadi, M., Biglari, M., & Bodaghi, M. (2024). Topology optimization of coronary artery stent considering structural and hemodynamic parameters. Heliyon, 10, e39452. https://doi.org/10.1016/j.heliyon.2024.e39452Cited by: 6

Chen, Y., Tillman, B., Go, C., Cho, S. K., Clark, W. W., Hur, T. B., Ding, Y., & Chun, Y. (2018). A novel customizable stent graft that contains a stretchable ePTFE with a laser-welded nitinol stent. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 107, 911–923. https://doi.org/10.1002/jbm.b.34186Cited by: 21

Goldman, J., Liu, S. Q., & Tefft, B. J. (2023). Anti-Inflammatory and Anti-Thrombogenic Properties of Arterial Elastic Laminae. Bioengineering, 10, 424. https://doi.org/10.3390/bioengineering10040424Cited by: 3

Janjic, M., Pappa, F., Karagkiozaki, V., Gitas, C., Ktenidis, K., & Logothetidis, S. (2017). Surface modification of endovascular stents with rosuvastatin and heparin-loaded biodegradable nanofibers by electrospinning. International Journal of Nanomedicine, Volume 12, 6343–6355. https://doi.org/10.2147/ijn.s138261Cited by: 41

Li, L., Terry, C. M., Shiu, Y.-T. E., & Cheung, A. K. (2008). Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney International, 74, 1247–1261. https://doi.org/10.1038/ki.2008.318Cited by: 168

Zhang, M., Tupin, S., Li, Y., & Ohta, M. (2021). Association Between Aneurysmal Haemodynamics and Device Microstructural Characteristics After Flow-Diversion Treatments With Dual Stents of Different Sizes: A Numerical Study. Frontiers in Physiology, 12. https://doi.org/10.3389/fphys.2021.663668Cited by: 8